Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Understanding what not to do when budgeting is crucial for financial success. Learn the common mistakes to steer clear of.
26,044 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Solana Foundation rolled out an AI agent thesis at a major New York summit, arguing a platform shift could redraw Sol...
VFVA has posted solid gains by targeting cheap U.S. equities, but a hidden volatility risk lies in its deep value app...
Navan stock soared today as the company posted solid growth and highlighted AI-driven efficiencies in its platform. T...
An experienced astronaut suddenly lost the ability to speak aboard the ISS, triggering a flurry of tests and question...
Bitcoin, XRP, Ethereum, and Solana have all declined 6-8% over the past week, dragging the crypto market lower amid E...
In a dramatic Q1, a bold Bitcoin-focused strategy posts a $12.5 billion loss. This article explains what happened, wh...
Investors often ask where XRP will be in three years. This article examines bear, base, and bull scenarios, plus prac...
A fresh, investor-ready look at StoneX's Q2 2026 results. This article breaks down the key numbers, what they mean fo...
A new wave of small modular reactors could reshape the US power mix. This article explains why NuScale Power is catch...
Payoneer’s quarterly results can illuminate how cross-border payments and freelance earnings ecosystems are evolving....
Chewy has faced a rough year, with shares falling and growth challenges ahead. Yet, a closer look under the hood show...